BCG-induced protection: Effects on innate immune memory

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 512-517

  Netea, Mihai G ^a   Van Crevel, Reinout ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCG; Innate immune memory; Trained immunity; Tuberculosis

Indexed keywords

BCG VACCINE;

BCG VACCINATION; CROSS REACTION; EPIGENETICS; HUMAN; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; INNATE IMMUNITY; RESPIRATORY TRACT INFECTION; REVIEW; TUBERCULOSIS; ADAPTIVE IMMUNITY; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETIC EPIGENESIS; HISTORY; IMMUNOLOGY; MICROBIOLOGY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VACCINATION;

ADAPTIVE IMMUNITY; BCG VACCINE; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84920003345     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.09.006     Document Type: Review

References (71)

1. Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med 1931, 24:1481-1490.
2. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116:180-183.
3. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
4. Salem A., Nofal A., Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol 2013, 30:60-63.
5. Metawea B., El-Nashar A.R., Kamel I., Kassem W., Shamloul R. Application of viable Bacille Calmette-Guerin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study. Urology 2005, 65:247-250.
6. Rousseau M.C., Parent M.E., St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol 2008, 19:438-448.
7. Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014, 58:470-480.
8. Weir R.E., Black G.F., Nazareth B., Floyd S., Stenson S., Stanley C., et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to Bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 2006, 146:390-399.
9. Setia M.S., Steinmaus C., Ho C.S., Rutherford G.W. The role of BCG in prevention of leprosy: a meta-analysis. The Lancet Infectious diseases 2006, 6:162-170.
10. Debacker M., Portaels F., Aguiar J., Steunou C., Zinsou C., Meyers W., Dramaix M., et al. Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 2006, 12:1325-1331.
11. Nackers F., Dramaix M., Johnson R.C., Zinsou C., Robert A., Biurrun Bakedano E., et al. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg 2006, 75:768-774.
12. Naeslund C. Expérience de vaccination par le BCG dans la province du Norrbotten (Suède). Revue de la Tuberculose 1931, 12:617-636.
13. Vaccination preventive de la tuberculose de l'homme et des animaux par le BCG. Rapports et documents provenant des divers pays (la France exceptee) transmis a l'institute Pasteur en 1932 1932, Mason & Cie, Paris.
14. Aronson J.D. Protective vaccination against tuberculosis, with special reference to BCG vaccine. Minn Med 1948, 31:1336.
15. Levine M.I., Sackett M.F. Results of BCG immunization in New York City. Am Rev Tuberc 1946, 53:517-532.
16. Ferguson R.G., Simes A.B. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949, 30:5-11.
17. Garly M.L., Martins C.L., Bale C., Baldé M.A., Hedegaard K.L., Gustafson P., et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?. Vaccine 2003, 21:2782-2790.
18. Lehmann D., Vail J., Firth M.J., de Klerk N.H., Alpers M.P. Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea. Int J Epidemiol 2005, 34:138-148.
19. Breiman R.F., Streatfield P.K., Phelan M., Shifa N., Rashid M., Yunus M. Effect of infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data. Lancet 2004, 364:2204-2211.
20. Moulton L.H., Rahmathullah L., Halsey N.A., Thulasiraj R.D., Katz J., Tielsch J.M. Evaluation of non-specific effects of infant immunizations on early infant mortality in a southern Indian population. Trop Med Int Health 2005, 10:947-955.
21. Shann F. The nonspecific effects of vaccines and the expanded program on immunization. J Infect Dis 2011, 204:182-184.
22. Shann F. The non-specific effects of vaccines. Arch Dis Child 2010, 95:662-667.
23. Aaby P., Roth A., Ravn H., Napirna B.M., Rodrigues A., Lisse I.M., et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. J Infect Dis 2011, 204:245-252.
24. Biering-Sorensen S., Aaby P., Napirna B.M., Roth A., Ravn H., Rodrigues A., et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J 2012, 31:306-308.
25. Aaby P., Benn C., Nielsen J., Lisse I.M., Rodrigues A., Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2012, 2.
26. Stensballe L.G., Nante E., Jensen I.P., Kofoed P.E., Poulsen A., Jensen H., et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 2005, 23:1251-1257.
27. Niobey F.M., Duchiade M.P., Vasconcelos A.G., de Carvalho M.L., Leal Mdo C., Valente J.G. Risk factors for death caused by pneumonia in children younger than 1 year old in a metropolitan region of southeastern Brazil. A case-control study. Rev Saude Publica 1992, 26:229-238.
28. Hollm-Delgado M.G., Stuart E.A., Black R.E. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics 2014, 133:e73-e81.
29. Chisti M.J., Salam M.A., Ahmed T., Shahid A.S., Shahunja K.M., Faruque A.S., et al. Lack of BCG vaccination and other risk factors for bacteraemia in severely malnourished children with pneumonia. Epidemiol Infect 2014, 1-5.
30. Elliott A.M., Nakiyingi J., Quigley M.A., French N., Gilks C.F., Whitworth J.A. Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda. Lancet 1999, 354:1000-1001.
31. Barreto M.L., Rodrigues L.C., Silva R.C., Assis A.M., Reis M.G., Santos C.A., et al. Lower hookworm incidence, prevalence, and intensity of infection in children with a Bacillus Calmette-Guerin vaccination scar. J Infect Dis 2000, 182:1800-1803.
32. Randall A.E., Perez M.A., Floyd S., Black G.F., Crampin A.C., Ngwira B., et al. Patterns of helminth infection and relationship to BCG vaccination in Karonga District, northern Malawi. Trans R Soc Trop Med Hyg 2002, 96:29-33.
33. Parra M., Liu X., Derrick S.C., Yang A., Tian J., Kolibab K., et al. Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS ONE 2013, 8:e66115.
34. Howard J.G., Biozzi G., Halpern B.N., Stiffel C., Mouton D. The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. Br J Exp Pathol 1959, 40:281-290.
35. Ritz N., Mui M., Balloch A., Curtis N. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. Vaccine 2013, 31:3098-3103.
36. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523.
37. Selin L.K., Nahill S.R., Welsh R.M. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J Exp Med 1994, 179:1933-1943.
38. Welsh R.M., Selin L.K. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002, 2:417-426.
39. Mathurin K.S., Martens G.W., Kornfeld H., Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009, 83:3528-3539.
40. Blanden R.V., Lefford M.J., Mackaness G.B. The host response to Calmette-Guerin bacillus infection in mice. J Exp Med 1969, 129:1079-1107.
41. Berg R.E., Crossley E., Murray S., Forman J. Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J Exp Med 2003, 198:1583-1593.
42. Netea M.G., Quintin J., van der Meer J.W. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011, 9:355-361.
43. Pham L.N., Dionne M.S., Shirasu-Hiza M., Schneider D.S. A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog 2007, 3:e26.
44. Rodrigues J., Brayner F.A., Alves L.C., Dixit R., Barillas-Mury C. Hemocyte differentiation mediates innate immune memory in Anopheles gambiae mosquitoes. Science 2010, 329:1353-1355.
45. Conrath U. Molecular aspects of defence priming. Trends Plant Sci 2011, 16:524-531.
46. Van Den Burg H.A., Takken F.L. Does chromatin remodeling mark systemic acquired resistance. Trends Plant Sci 2009, 14:286-294.
47. Slaughter A., Daniel X., Flors V., Luna E., Hohn B., Mauch-Mani B. Descendants of primed Arabidopsis plants exhibit resistance to biotic stress. Plant Physiol 2012, 158:835-843.
48. Bistoni F., Vecchiarelli A., Cenci E., Puccetti P., Marconi P., Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 1986, 51:668-674.
49. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
50. Lopez-Verges S., Milush J.M., Schwartz B.S., Pando M.J., Jarjoura J., York V.A., et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 2011, 108:14725-14732.
51. Paust S., Gill H.S., Wang B.Z., Flynn M.P., Moseman E.A., Senman B., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010, 11:1127-1135.
52. Beeson P.B. Tolerance to bacterial pyrogens: I. Factors influencing its development. J Exp Med 1947, 86:29-38.
53. Draisma A., Pickkers P., Bouw M.P., van der Hoeven J.G. Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009, 37:1261-1267.
54. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
55. Clarke T.B., Davis K.M., Lysenko E.S., Zhou A.Y., Yu Y., Weiser J.N. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010, 16:228-231.
56. Quintin J., Saeed S., Martens J.H., Giamarellos-Bourboulis E.J., Ifrim D.C., Logie C., et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012, 12:223-232.
57. Marakalala M.J., Williams D.L., Hoving J.C., Engstad R., Netea M.G., Brown G.D. Dectin-1 plays a redundant role in the immunomodulatory activities of beta-glucan-rich ligands in vivo. Microbes Infect 2013, 15:511-515.
58. Tribouley J., Tribouley-Duret J., Appriou M. Effect of Bacillus Callmette-Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni. C R Seances Soc Biol Fil 1978, 172:902-904.
59. Van't Wout J.W., Poell R., van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 1992, 36:713-719.
60. Kleinnijenhuis J., Quintin J., Preijers F., Joosten L.A., Ifrim D.C., Saeed S., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012, 109:17537-17542.
61. Kleinnijenhuis J., Quintin J., Preijers F., Benn C.S., Joosten L.A., Jacobs C., et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2013, 6:152-158.
62. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
63. McShane H. Understanding BCG is the key to improving it. Clin Infect Dis 2014, 58:481-482.
64. Verrall A.J., Netea M.G., Alisjahbana B., Hill P.C., van Crevel R. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology 2014, 141:506-513.
65. Soysal A., Millington K.A., Bakir M., Dosanjh D., Aslan Y., Deeks J.J., et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005, 366:1443-1451.
66. Chan P.C., Yang C.H., Chang L.Y., Wang K.F., Kuo Y.C., Lin C.J., et al. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax 2013, 68:263-268.
67. Michelsen S.W., Soborg B., Koch A., Carstensen L., Hoff S.T., Agger E.M., et al. The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. Thorax 2014, 69:851-856.
68. Basu Roy R., Sotgiu G., Altet-Gomez N., Tsolia M., Ruga E., Velizarova S., et al. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 2012, 186:378-384.
69. Eriksen J., Chow J.Y., Mellis V., Whipp B., Walters S., Abrahamson E., et al. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold. Thorax 2010, 65:1067-1071.
70. Roy A., Eisenhut M., Harris R.J., Rodrigues L.C., Sridhar S., Habermann S., et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014, 349:g4643.
71. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis Bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.